Pyxis Oncology, Inc.
PYXS
$2.62
$0.020.77%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -14.17% | -82.53% | -82.53% | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.17% | -82.53% | -82.53% | -100.00% | -- |
| Cost of Revenue | 402.74% | -100.00% | -100.00% | -100.00% | -- |
| Gross Profit | -26.81% | -82.00% | -82.00% | -100.00% | -- |
| SG&A Expenses | -12.78% | -18.00% | -30.52% | -30.29% | -27.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.12% | 6.13% | 4.26% | 3.36% | 1.61% |
| Operating Income | -24.82% | -28.37% | -25.47% | -29.32% | 18.47% |
| Income Before Tax | 1.59% | -72.55% | -65.81% | -68.50% | -7.73% |
| Income Tax Expenses | 164.05% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.96% | -69.27% | -62.64% | -64.75% | -4.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.96% | -69.27% | -62.64% | -64.75% | -4.80% |
| EBIT | -24.82% | -28.37% | -25.47% | -29.32% | 18.47% |
| EBITDA | -23.56% | -31.38% | -27.51% | -31.38% | 20.26% |
| EPS Basic | -0.20% | -50.13% | -25.05% | -12.73% | 31.46% |
| Normalized Basic EPS | -29.55% | -20.43% | -0.29% | 9.42% | 47.91% |
| EPS Diluted | -0.20% | -50.13% | -25.05% | -12.73% | 31.46% |
| Normalized Diluted EPS | -29.55% | -20.43% | -0.29% | 9.42% | 47.91% |
| Average Basic Shares Outstanding | 6.34% | 13.73% | 23.95% | 38.76% | 46.50% |
| Average Diluted Shares Outstanding | 6.34% | 13.73% | 23.95% | 38.76% | 46.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |